person · Reporting owner

DAWES KAREN A

Disclosed activity across 3 companies

Tapewire entity: 46694
SEC CIK: 0001261506

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Assertio Therapeutics, IncASRT · Entity 149352	Director	May 08, 2020	May 12, 2020
REPLIGEN CORPRGEN · Entity 486	Director	May 14, 2026	May 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Assertio Therapeutics, Inc

Report date May 08, 2020 · Filed May 12, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	84,589	Reported balance After 2020-05-08 transaction · row 1 1 source row Row 1 · 2020-05-08 · Sale · Disposed 15,834 · Balance 84,589 F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019.

F2: The price reported is a weighted average sale price. The shares were sold in multiple same-way transactions on May 8, 2020 at prices ranging from $0.7562 to $0.8245 per share of common stock. If requested by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares of common stock sold at each separate price.

REPLIGEN CORP

Report date May 14, 2026 · Filed May 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	92,816	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 995 · Balance 92,816 F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14	Direct	2,239	Reported balance After 2026-05-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Filing footnotes · ownership attribution and instrument terms

F1: Ms. Dawes was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Barinthus Biotherapeutics plc.

Report date September 09, 2026 · Filed September 09, 2026

Section 16 reporting ended · disclosed 2026-09-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2026-09-09 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-09 · Disposition to issuer · Disposed 1,700 · Balance 0 F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share. F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-05-01	Direct	Reported balance After 2026-09-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-09-09 · Disposition to issuer · Disposed 34,328 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.27 · Expires 2032-06-15	Direct	Reported balance After 2026-09-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-09 · Disposition to issuer · Disposed 18,604 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2033-05-11	Direct	Reported balance After 2026-09-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-09-09 · Disposition to issuer · Disposed 19,197 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2034-05-10	Direct	Reported balance After 2026-09-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-09 · Disposition to issuer · Disposed 19,516 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-06-10	Direct	Reported balance After 2026-09-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-09 · Disposition to issuer · Disposed 20,174 · Balance 0 F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco. F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time. F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.

F2: This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc. ("Topco"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the "Effective Time"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the "Scheme") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco.

F3: Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the "Topco Common Stock").

F4: Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	532	$303.48	$161,451.36	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,354 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $303.48 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.89 to $303.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	446	$301.97	$134,678.62	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,886 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $301.97 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.71 to $302.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	251	$301.20	$75,601.20	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,332 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $301.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.70 to $301.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 02, 2021 Filed Nov 4, 2021 21:41 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	64	$299.02	$19,137.28	Disclosure SEC source: 0000899243-21-043038 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,583 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:46 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	27	$295.82	$7,987.14	Disclosure SEC source: 0000899243-21-036134 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,647 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $295.82 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $295.79 to $295.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:46 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	108	$295.02	$31,862.16	Disclosure SEC source: 0000899243-21-036134 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,674 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $295.02 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $294.75 to $295.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:46 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	101	$294.06	$29,700.06	Disclosure SEC source: 0000899243-21-036134 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,782 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $294.06 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.64 to $294.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:46 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	25	$292.34	$7,308.50	Disclosure SEC source: 0000899243-21-036134 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,883 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $292.34 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $292.17 to $292.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 14, 2021 Filed Sep 15, 2021 21:46 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	13	$290.02	$3,770.26	Disclosure SEC source: 0000899243-21-036134 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,908 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	3,459	$0.00 Strike: $38.76	$0.00	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · derivative · entry 8 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,459 shares Expires 2027-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	851	$285.44	$242,909.44	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,921 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F7 · price: $285.44 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $285.19 to $285.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,107	$284.64	$315,096.48	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,772 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F6 · price: $284.64 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $284.18 to $285.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	661	$283.56	$187,433.16	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,879 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $283.56 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.16 to $284.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	405	$282.53	$114,424.65	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,540 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $282.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.10 to $282.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	196	$281.68	$55,209.28	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,945 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $281.68 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.08 to $282.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	239	$280.27	$66,984.53	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,141 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $280.27 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.90 to $280.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
September 01, 2021 Filed Sep 2, 2021 20:29 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	3,459	$38.76	$134,070.84	Disclosure SEC source: 0000899243-21-034897 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	40	$262.31	$10,492.40	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 11 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,921 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	78	$260.91	$20,350.98	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 10 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,961 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F10 · price: $260.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.80 to $261.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	388	$259.93	$100,852.84	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 9 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,039 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F9 · price: $259.93 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.39 to $260.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	634	$258.91	$164,148.94	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 8 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,427 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F8 · price: $258.91 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.32 to $259.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 18, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	302	$257.66	$77,813.32	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 7 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,061 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F7 · price: $257.66 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.14 to $258.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	194	$256.43	$49,747.42	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,363 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	2,231	$255.07	$569,061.17	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,557 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F6 · price: $255.07 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.73 to $255.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	8,580	$254.09	$2,180,092.20	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,788 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $254.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.71 to $254.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	4,665	$253.34	$1,181,831.10	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,368 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $253.34 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.69 to $253.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	920	$251.92	$231,766.40	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,033 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $251.92 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.66 to $252.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
August 17, 2021 Filed Aug 19, 2021 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	924	$251.15	$232,062.60	Disclosure SEC source: 0000899243-21-033643 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,953 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $251.15 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.63 to $251.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:25 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	614	$203.11	$124,709.54	Disclosure SEC source: 0000899243-21-029561 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,877 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $203.11 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.78 to $203.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:25 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	2,877	$202.29	$581,988.33	Disclosure SEC source: 0000899243-21-029561 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,491 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $202.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.76 to $202.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:25 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	806	$201.37	$162,304.22	Disclosure SEC source: 0000899243-21-029561 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,368 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $201.37 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.76 to $201.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 20, 2021 Filed Jul 23, 2021 00:25 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	288	$200.01	$57,602.88	Disclosure SEC source: 0000899243-21-029561 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,174 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $200.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.56 to $200.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 15, 2021 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	2,929	$0.00 Strike: $41.19	$0.00	Disclosure SEC source: 0000899243-21-028505 · doc4.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,929 shares Expires 2025-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
July 13, 2021 Filed Jul 15, 2021 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	1,520	$202.23	$307,389.60	Disclosure SEC source: 0000899243-21-028505 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,462 F1 · price: $202.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.27 to $204.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 15, 2021 21:17 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	2,929	$41.19	$120,645.51	Disclosure SEC source: 0000899243-21-028505 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	2,929	$0.00 Strike: $41.19	$0.00	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · derivative · entry 6 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,929 shares Expires 2025-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	5	$204.02	$1,020.10	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · nonDerivative · entry 5 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,462 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F5 · price: $204.02 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.01 to $204.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	444	$203.09	$90,171.96	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,467 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F4 · price: $203.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.86 to $203.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	630	$202.29	$127,442.70	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,911 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F3 · price: $202.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.77 to $202.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	441	$201.27	$88,760.07	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,541 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021. F2 · price: $201.27 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.77 to $201.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
July 13, 2021 Filed Jul 22, 2021 22:53 UTC Amendment	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	2,929	$41.19	$120,645.51	Disclosure SEC source: 0000899243-21-029533 · doc4a.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 13, 2021 Filed May 18, 2021 01:50 UTC	REPLIGEN CORP RGEN · Entity 486	GrantStock Option (Right to Buy) · Derivative	1,522	$0.00 Strike: $169.65	$0.00	Disclosure SEC source: 0000899243-21-019705 · doc4.xml · derivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,522 Underlying: Common Stock · 1,522 shares Expires 2031-05-13 F2 · derivative.exercise_date: Award vests in full on the earlier of May 13, 2022, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. Read SEC document
May 13, 2021 Filed May 18, 2021 01:50 UTC	REPLIGEN CORP RGEN · Entity 486	GrantCommon Stock	604	$0.00	$0.00	Disclosure SEC source: 0000899243-21-019705 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,053 F1 · shares: Ms. Dawes was awarded 604 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 13, 2022, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document
May 11, 2021 Filed May 13, 2021 21:01 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $3.22	$0.00	Disclosure SEC source: 0000899243-21-019419 · doc4.xml · derivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
May 11, 2021 Filed May 13, 2021 21:01 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	285	$176.85	$50,402.25	Disclosure SEC source: 0000899243-21-019419 · doc4.xml · nonDerivative · entry 2 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,449 F1 · price: $176.85 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.73 to $176.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
May 11, 2021 Filed May 13, 2021 21:01 UTC	REPLIGEN CORP RGEN · Entity 486	Exercise / conversionCommon Stock	15,000	$3.22	$48,300.00	Disclosure SEC source: 0000899243-21-019419 · doc4.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 04, 2021 Filed May 6, 2021 16:29 UTC	Barinthus Biotherapeutics plc. VACC · Entity 9597	PurchaseOrdinary Shares	1,700	$17.00	$28,900.00	Disclosure SEC source: 0001104659-21-062434 · tm2115262-7_4seq1.xml · nonDerivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
April 29, 2021 Filed May 4, 2021 20:25 UTC	Barinthus Biotherapeutics plc. VACC · Entity 9597	GrantShare Option (Right to Buy) · Derivative	34,328	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001104659-21-061224 · tm2114558-20_4seq1.xml · derivative · entry 1 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,328 Underlying: Ordinary Shares · 34,328 shares Expires 2031-04-29 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document
June 18, 2020 Filed Jun 22, 2020 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	2,568	$116.56	$299,326.08	Disclosure SEC source: 0000899243-20-017371 · doc4.xml · nonDerivative · entry 4 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,734 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F5 · price: $116.56 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.20 to $116.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
June 18, 2020 Filed Jun 22, 2020 20:42 UTC	REPLIGEN CORP RGEN · Entity 486	SaleCommon Stock	8,217	$115.76	$951,199.92	Disclosure SEC source: 0000899243-20-017371 · doc4.xml · nonDerivative · entry 3 DAWES KAREN A · CIK 0001261506 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,302 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on March 19, 2020. F4 · price: $115.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.20 to $116.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.